Eckert & Ziegler and the Nuclear Physics Institute of the Czech Academy of Sciences have significantly increased the production volume of their joint actinium-225 (Ac-225) initiative.
With the successful transition to larger-scale manufacturing of the radioisotope, using facilities in Řež, Czech Republic, and Braunschweig, Germany, the partners are now one of a small number of suppliers able to provide clinically relevant quantities of Ac-225, they said.
Although considered one of the most promising alpha-emitting radionuclides for targeted radiopharmaceutical applications, particularly in the treatment of small tumors and micrometastases, Ac-225 production has been constrained by restricted availability and the technical complexity of isotope production, they added.
With more than 1,000 employees, Eckert & Ziegler supplies isotope-related components for nuclear medicine and radiation therapy -- including gallium-68, lutetium-177, yttrium-90, and Ac-225 -- to pharmaceutical companies and research institutions worldwide.
